SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001654954-24-001310 from TENAX THERAPEUTICS, INC. (TENX)

TENAX THERAPEUTICS, INC.
Date: Feb. 5, 2024 · CIK: 0000034956 · Accession: 0001654954-24-001310

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-275856

Date
February 5, 2024
Author
President
Form
CORRESP
Company
TENAX THERAPEUTICS, INC.

Letter

tenx_corresp

Roth Capital Partners, LLC

888 San Clemente Drive, Suite 400

Newport Beach, CA 92660

February 5, 2024

VIA EDGAR CORRESPONDENCE

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re:

Tenax Therapeutics, Inc.

Registration Statement on Form S-1

File No. 333-275856

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, the placement agent, hereby request that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced registration statement on Form S-1 (the “Registration Statement”) to become effective at 5:30 p.m., Eastern time, on Tuesday, February 6, 2024, or as soon thereafter as practicable.

Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated February 2, 2024 to agents, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned, as placement agent, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Very
truly yours,
ROTH CAPITAL PARTNERS, LLC

Show Raw Text
CORRESP
1
filename1.htm

tenx_corresp

Roth Capital Partners, LLC

888 San Clemente Drive, Suite 400

Newport Beach, CA 92660

February 5, 2024

VIA EDGAR CORRESPONDENCE

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

100 F
Street, N.E.

Washington,
D.C. 20549

Re:

Tenax
Therapeutics, Inc.

Registration
Statement on Form S-1

File
No. 333-275856

Ladies
and Gentlemen:

Pursuant to Rule
461 of the General Rules and Regulations under the Securities Act
of 1933, as amended (the “Act”), we, the placement
agent, hereby request that the Securities and Exchange Commission
(the “Commission”) take appropriate action to cause the
above-referenced registration statement on Form S-1 (the
“Registration Statement”) to become effective at 5:30
p.m., Eastern time, on Tuesday, February 6, 2024, or as soon
thereafter as practicable.

Pursuant to Rule
460 under the Act, we wish to advise you that we have distributed
as many copies of the Preliminary Prospectus dated February 2, 2024
to agents, dealers, institutions and others as appears to be
reasonable to secure adequate distribution of the preliminary
prospectus.

The
undersigned, as placement agent, has complied and will comply with
Rule 15c2-8 under the Securities Exchange Act of 1934, as
amended.

Very
truly yours,

ROTH CAPITAL PARTNERS, LLC

By: /s/ Aaron M.
Gurewitz

Aaron M. Gurewitz

President

cc:

M. Ali Panjwani,
Esq.

Pryor
Cashman LLP